SCHLIEREN

Memo Therapeutics increases Series C financing to CHF 45 million

Retrieved on: 
Tuesday, May 7, 2024
FDA, Phase, Cancer, Venture round, BK, Kidney, Risk, MTX, BK virus, Viremia, Memo, Disease, Patient, Kidney transplantation, BKV, CHF, Infection, Therapy, Viral, Pharmaceutical industry

Schlieren / Zurich, Switzerland, 7 May, 2024 – Memo Therapeutics AG (or “MTx”), a late-stage biotech company developing a best-in-class BKV-neutralizing antibody for BKV infection in kidney transplantation, today announces that it has successfully raised CHF 20 million as part of an extension of its Series C financing, bringing the total amount raised in the funding round to CHF 45 million.

Key Points: 
  • Schlieren / Zurich, Switzerland, 7 May, 2024 – Memo Therapeutics AG (or “MTx”), a late-stage biotech company developing a best-in-class BKV-neutralizing antibody for BKV infection in kidney transplantation, today announces that it has successfully raised CHF 20 million as part of an extension of its Series C financing, bringing the total amount raised in the funding round to CHF 45 million.
  • Erik van den Berg, CEO of Memo Therapeutics, commented: “This financing provides further external endorsement of the potential of our highly potent anti-BK virus mAb and our clinical strategy to bring it to patients as quickly as possible.
  • Thomas Harth, Principal at Ysios Capital stated: “We believe Memo Therapeutics has developed a very powerful antibody that can address the growing concern of BKV infections in kidney transplant recipients.
  • Alongside AntiBKV, Memo Therapeutics is developing a panel of pre-clinical assets in cancer and viral infections.

Memo Therapeutics increases Series C financing to CHF 45 million

Retrieved on: 
Tuesday, May 7, 2024
FDA, Phase, Cancer, Venture round, BK, Kidney, Risk, MTX, BK virus, Viremia, Memo, Disease, Patient, Kidney transplantation, BKV, CHF, Infection, Therapy, Viral, Pharmaceutical industry

Schlieren / Zurich, Switzerland, 7 May, 2024 – Memo Therapeutics AG (or “MTx”), a late-stage biotech company developing a best-in-class BKV-neutralizing antibody for BKV infection in kidney transplantation, today announces that it has successfully raised CHF 20 million as part of an extension of its Series C financing, bringing the total amount raised in the funding round to CHF 45 million.

Key Points: 
  • Schlieren / Zurich, Switzerland, 7 May, 2024 – Memo Therapeutics AG (or “MTx”), a late-stage biotech company developing a best-in-class BKV-neutralizing antibody for BKV infection in kidney transplantation, today announces that it has successfully raised CHF 20 million as part of an extension of its Series C financing, bringing the total amount raised in the funding round to CHF 45 million.
  • Erik van den Berg, CEO of Memo Therapeutics, commented: “This financing provides further external endorsement of the potential of our highly potent anti-BK virus mAb and our clinical strategy to bring it to patients as quickly as possible.
  • Thomas Harth, Principal at Ysios Capital stated: “We believe Memo Therapeutics has developed a very powerful antibody that can address the growing concern of BKV infections in kidney transplant recipients.
  • Alongside AntiBKV, Memo Therapeutics is developing a panel of pre-clinical assets in cancer and viral infections.

CDR-Life to Present Tumor Targeting Capabilities of M-gager® Platform at the TCR-Based Therapies for Solid Tumors Summit

Retrieved on: 
Tuesday, April 23, 2024
TCE, MHC, Antibody

ZÜRICH, Switzerland, April 23, 2024 (GLOBE NEWSWIRE) -- CDR-Life Inc. today announced a presentation on its proprietary antibody-major histocompatibility complex (MHC) technology for the development of highly specific T-cell engagers (TCE) at the TCR-Based Therapies for Solid Tumors Summit, occurring April 23-25 in Boston, Massachusetts.

Key Points: 
  • ZÜRICH, Switzerland, April 23, 2024 (GLOBE NEWSWIRE) -- CDR-Life Inc. today announced a presentation on its proprietary antibody-major histocompatibility complex (MHC) technology for the development of highly specific T-cell engagers (TCE) at the TCR-Based Therapies for Solid Tumors Summit, occurring April 23-25 in Boston, Massachusetts.
  • The presentation will discuss how antibodies targeting tumor peptides on the MHC enable T-cells access to an untapped reservoir of intracellular tumor antigens and will highlight the M-gager® technology’s ability to leverage the potency, versatility and manufacturability of antibodies to revolutionize cancer immunotherapy.

CDR-Life Unveils Results on T-Cell Engagers Targeting Hard-to-Treat Solid Tumors at AACR 2024

Retrieved on: 
Friday, April 5, 2024
Cell, Trichloroethylene, Patient, Lung, Epitope, Breast, KK, Allele, AACR, Cancer, Antibody, TCE, Therapy, Peptide, Vaccine

Identifying a TCE against the KK-LC-1 peptide on HLA-A*01 will provide an option for patients that do not benefit from the more common HLA-A*02 targeting therapeutics currently in development.

Key Points: 
  • Identifying a TCE against the KK-LC-1 peptide on HLA-A*01 will provide an option for patients that do not benefit from the more common HLA-A*02 targeting therapeutics currently in development.
  • However, high levels of similar off-target peptides presented in healthy tissues make targeting the KK-LC-1/HLA-A*01 challenging.
  • CDR-Life’s data gathered on pMHC TCE antibodies with high specificity towards HLA-A*01 restricted KK-LC-1 epitopes demonstrate the antibodies’ promising anti-tumor activity and specificity for KK-LC-1/HLA-A*01 positive tumors.
  • In vitro studies showed significantly higher TCE-dependent T-cell activation towards cells presenting the target peptide compared to the risk peptides.

Memo Therapeutics AG Strengthens Management Team

Retrieved on: 
Monday, February 5, 2024
Leiden University, Bachelor of Science, Supply chain management, CMC, Chemistry, Wageningen University & Research, PPD, Maartje (name), Master of Science, MTX, AbbVie, Barton College, Doctor of Philosophy, Viral, Nursing, Pharmaceutical industry

Ms. Clemmer is an accomplished global clinical research leader with over 20 years of experience directing international clinical operations.

Key Points: 
  • Ms. Clemmer is an accomplished global clinical research leader with over 20 years of experience directing international clinical operations.
  • Ms. Clemmer previously held senior leadership positions at the Contract Research Organizations PRA Health Sciences and PPD.
  • She joins MTx from AM-Pharma, where she was responsible for all drug substance activities including Phase III clinical manufacturing.
  • Eric van den Berg, CEO of MTx, commented: “It is a pleasure to welcome Kristie and Maartje to MTx.

Neurimmune to regain global rights to brain amyloid depleter for the treatment of Alzheimer’s disease

Retrieved on: 
Wednesday, January 31, 2024
Amyloid, Therapy, Patient, FDA, Antibody, Brain, Disease, Dementia, GMP, Medical imaging

ZURICH, Switzerland, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Neurimmune announced today that it regained global rights to aducanumab, a recombinant human antibody developed to deplete brain amyloid.

Key Points: 
  • ZURICH, Switzerland, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Neurimmune announced today that it regained global rights to aducanumab, a recombinant human antibody developed to deplete brain amyloid.
  • Neurimmune licensed its antibody aducanumab for the treatment and prevention of Alzheimer’s disease to Biogen in 2007 and will hold global rights to the program following Biogen’s termination of the collaboration and license agreement.
  • Alzheimer’s disease - the leading cause of dementia in elderly people - is characterized by a decades-long build-up in the brain of a protein known as amyloid.
  • “The depletion of brain amyloid is a validated therapeutic target for the treatment of Alzheimer’s disease,” said Christoph Hock, Chief Medical Officer of Neurimmune.

CDR-Life Announces FDA Clearance of IND Application for CDR404 for Treatment of Solid Tumors

Retrieved on: 
Tuesday, January 23, 2024
Investigational New Drug, NSCLC, Cancer, IND, Food, Lung cancer, FDA, Pharmaceutical industry

ZURICH, Switzerland, Jan. 23, 2024 (GLOBE NEWSWIRE) -- CDR-Life Inc. today announced the clearance of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for CDR404, its lead program in development as a precision immunotherapy for solid tumors.

Key Points: 
  • ZURICH, Switzerland, Jan. 23, 2024 (GLOBE NEWSWIRE) -- CDR-Life Inc. today announced the clearance of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for CDR404, its lead program in development as a precision immunotherapy for solid tumors.
  • “CDR404 holds the potential to become the off-the-shelf therapy for multiple cancers expressing MAGE-A4 with high unmet need, including non-small cell lung cancer (NSCLC),” said Christian Leisner, Ph.D., Chief Executive Officer at CDR-Life.
  • “We are thrilled to achieve this milestone and are continuing to advance several additional programs leveraging our M-gager® technology against promising intracellular cancer targets with the goal of improving patient lives.”
    The company anticipates initiating Phase 1 trial enrollment in the coming months.

CDR-Life Announces First Patient Dosed in Phase 1 Study with Boehringer Ingelheim Evaluating Potential Treatment for Geographic Atrophy

Retrieved on: 
Wednesday, December 6, 2023
Pharmacokinetics, Ageing, Patient, Geographic atrophy, AMD, Safety, Retina, Boehringer Ingelheim, Pathology, Pharmaceutical industry

ZÜRICH, Switzerland, Dec. 06, 2023 (GLOBE NEWSWIRE) -- CDR-Life Inc. today announced that the first patient has been dosed in the Phase 1 trial of BI 771716 for the treatment of geographic atrophy (GA).

Key Points: 
  • ZÜRICH, Switzerland, Dec. 06, 2023 (GLOBE NEWSWIRE) -- CDR-Life Inc. today announced that the first patient has been dosed in the Phase 1 trial of BI 771716 for the treatment of geographic atrophy (GA).
  • Licensed to Boehringer Ingelheim, BI 771716 is a highly specific antibody fragment of reduced size, enabling an optimized penetration through all retinal layers to the most critical target site driving GA disease pathology.
  • More than 5 million people worldwide suffer from GA, of which more than 40% are legally blind.
  • GA worsens with age, affecting 1 in 29 people above the age of 75 and 1 in 4 people above 90.

CDR-Life Presents Findings from Two Studies in Preparation of Phase 1 Trial with Immunotherapy CDR404 for Treatment of Solid Tumors at SITC 2023

Retrieved on: 
Friday, November 3, 2023
TCGA, TCE, CD3, QSP, SITC, Immunotherapy, Fragment crystallizable region, Database, Immunohistochemistry, Epithelium, Messenger, Annual general meeting, Society, Patient, Vaccine, Medical imaging

ZÜRICH, Switzerland, Nov. 03, 2023 (GLOBE NEWSWIRE) -- CDR-Life Inc., in the run-up to initiation of its first Phase 1 clinical trial, presented two posters for CDR404, a first-of-its-kind, antibody-based, bivalent & bispecific MAGE-A4 T-cell engager (TCE) targeting MAGE-A4, an intracellular cancer protein with expression in several frequent and difficult to treat solid tumors, at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting.

Key Points: 
  • The demonstration of high MAGE-A4 protein expression in SQ-NSCLC and potent preclinical cytotoxicity of CDR404, highlights the therapeutic promise of CDR404 in HLA-A*02:01+ patients with SQ-NSCLC.
  • “These milestones underscore the continued advancement of CDR404’s potential as an off-the-shelf precision immunotherapy for MAGE-A4+ solid tumors.
  • Treatment with four different doses of CDR404 induced complete tumor regression in the in vivo SQ-NSCLC NCI-H1703 xenograft model.
  • The QSP model predicted doses of CDR404 which might have the most favorable benefit-risk profile for patients in the Phase 1 trial.

CDR-Life Presents Precise Tumor and Patient Selection for CDR404: First-of-its-Kind Dual MAGE-A4 T-cell Engager, at ESMO Congress 2023

Retrieved on: 
Monday, October 23, 2023
Bispecific monoclonal antibody, The Cancer Genome Atlas, Adenocarcinoma, TCGA, TCE, NSCLC, ESMO, IHC, HPV, Data, Head, Bladder cancer, Neck, Neoplasm, Histology, Messenger, Bivalent, Patient, HLA, Vaccine

ZÜRICH, Switzerland, Oct. 23, 2023 (GLOBE NEWSWIRE) -- CDR-Life Inc. presented findings on tumor target expression and precise patient selection for the upcoming Phase 1 trial of CDR404 (Abstract 200P), a first-of-its-kind bispecific and bivalent antibody fragment-based T-cell engager (TCE) targeting MAGE-A4, an intracellular protein which is presented on HLA-A*02:01 on the surface of cancer cells, at the ESMO Congress 2023, occurring October 20-24 in Madrid, Spain.

Key Points: 
  • The key objective of this study was for CDR-Life to explore MAGE-A4 expression levels in solid tumors using The Cancer Genome Atlas (TCGA) mRNA dataset.
  • In addition, subgroups of high MAGE-A4 expression were present across a wide range of solid cancers including lung adenocarcinoma, ovarian and gastric cancers.
  • “CDR404 is a novel, bispecific and bivalent T-cell engager differentiated from previous solid tumor T-cell engagers targeting MAGE-A4 in the clinic.
  • The MAGE-A4 mRNA distribution profiles across multiple tumor types indicate, that a tumor MAGE-A4 assay will be indispensable for trial screening.